Retrospective

Lana Lam

Telephone, Telephone:26323221,Fax, Fax:26492397,

email. email:wbchan@cuhk.edu.hk

Dr Wing Bun Chan

Telephone, Telephone:26323221,Fax, Fax:26492397,

email email:wbchan@cuhk.edu.hk

Yes

2003-04-23

Drug

Primary intervention: Rosiglitasone or Placebo for 52 weeks. Secondary intervention: Standard advice on lifestyle modification.

52 weeks

Matching placebo tablets

Inclusion Criteria 1. Type 2 diabetic patients above 18 years of age. 2. Newly diagnosed diabetes within one year with HbA1c less than or equals 7.0% at time of study entry. 3. No history of exposure to any anti-diabetic medications except diet control or insulin during period of gestational diabetes. 4. Alcohol consumption less than 50g/day.

Exclusion Criteria 1. Significantly impaired renal function with plasma creatinine > 200ƒÝmol/l. 2. Known case of cirrhosis (Child's B grading or above) or significant impaired liver function (ALT or AST greater than 2 times upper limit of normal). 3. Congestive heart failure of class III or IV NYHA 4. Progressive fatal disease 5. History of drug or alcohol abuse 6. History of hypersensitivity to study medication or drugs with similar chemical structure 7. Pregnant women , or those planning a pregnancy 8. Lactation 9. Known severe non-compliance to medication or any factor which will affect the completion of the study as judge by the investigator. 10. Need of any medication which will affect the interpretation of OGTT such as regular oral steroid or episodic high dose steroid.

Randomized

Placebo

Double-blind

Parallel

No